ArticleCancers2010
The evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature.
Article in Cancers, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 81 citations in OpenAlex.
- Review
- The value of preoperative molecular testing in the management of Bethesda V and Bethesda VI thyroid tumors.Hormones (Athens, Greece) · 2025Review
- Circulating Biomarkers of Thyroid Cancer: An Appraisal.Journal of clinical medicine · 2025Review
- Detection of genetic mutations in 855 cases of papillary thyroid carcinoma by next generation sequencing and its clinicopathological features.Diagnostic pathology · 2024Article
- Article
- Comparative analysis through propensity score matching in thyroid cancer: unveiling the impact of multiple malignancies.Frontiers in endocrinology · 2024Article
- Metastatic papillary thyroid carcinoma in pleural effusion: a case report and review of the literature.Journal of medical case reports · 2023Review
- Advances in Molecular Profiling and Their Potential Influence on the Extent of Surgery in Well-Differentiated Thyroid Carcinoma (WDTC).Life (Basel, Switzerland) · 2023Article
- Circulating microRNA as potential diagnostic and prognostic biomarkers of well-differentiated thyroid cancer: A review article.Cancer biomarkers : section A of Disease markers · 2023Review
- Thyroid Cancer Screening Using Tumor-Associated DN T Cells as Immunogenomic Markers.Frontiers in oncology · 2022Article
- Molecular Chaperones and Thyroid Cancer.International journal of molecular sciences · 2021Review
- Plasma Lipidomics Profiling Reveals Biomarkers for Papillary Thyroid Cancer Diagnosis.Frontiers in cell and developmental biology · 2021Article
- Molecular Markers Guiding Thyroid Cancer Management.Cancers · 2020Review
- Article
- Identification of potential novel biomarkers to differentiate malignant thyroid nodules with cytological indeterminate.BMC cancer · 2020Article
- Article
- The Blood Biomarkers of Thyroid Cancer.Cancer management and research · 2020Review
- Expression based biomarkers and models to classify early and late-stage samples of Papillary Thyroid Carcinoma.PloS one · 2020Article
- Review
- Promoter Methylation of Four Tumor Suppressor Genes in Human Papillary Thyroid Carcinoma.Iranian journal of pathology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid cancer is the most common malignancy of the endocrine system. The diagnosis of thyroid nodules, made by neck examination and ultrasonography, is a common event occurring in over 50% of the patient population over the age of 50. Yet, only 5% of these patients will be diagnosed with cancer. Fine needle aspiration biopsy is the gold standard for diagnosing thyroid nodules. However, 10-15% of these biopsies are inconclusive, ultimately requiring a diagnostic thyroid lobectomy. Consequently, research in thyroid biomarkers has become an area of active interest. In the 40 years since calcitonin was first described as the biomarker for medullary thyroid cancer, new biomarkers in thyroid cancer have been discovered. Advances in genomic and proteomic technologies have defined many of these novel thyroid biomarkers. The purpose of this article is to provide a comprehensive literature review of how these biomarkers have evolved from simple screening tests into a complex array of multiple markers to help predict the malignant potential and genetic signature of thyroid neoplasms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.